相关实验视频
Updated: Jun 19, 2025

06:08
A Novel Method: Super-selective Adrenal Venous Sampling
Published on: September 15, 2017
23.4K
原发性阿尔多斯特主义对功能的影响:来自SPAIN-ALDO注册表的结果
Marta Araujo-Castro1,2, Miguel Paja Fano3,4, Marga González-Boillos5
1Endocrinology & Nutrition Department, Hospital Universitario Ramón y Cajal Madrid.
Journal of hypertension
|July 25, 2024
概括
主要的阿尔多斯特症会影响功能,慢性病 (CKD) 影响10%的患者. 手术和矿物质皮质类受体抗剂 (MRA) 治疗最初都会降低功能,但上腺切除术可以提供更好的长期保护.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内分泌学 在内分泌学.
- 心血管医学 心血管医学
背景情况:
- 初级阿尔多斯类特征是过度生产阿尔多斯,导致高血压和电解质失衡.
- 过多的阿尔多激素越来越被认为是导致损伤和心血管并发症的直接因素.
- 了解原发性阿尔多斯泰龙症对功能的影响对于指导治疗策略至关重要.
研究的目的:
- 评估阿尔多素过量对原发性阿尔多素症患者功能的影响.
- 为了比较经过手术 (上腺切除术) 后的功能变化与医疗 (矿物甲基皮质受体抗剂 - MRA) 治疗.
- 在这个人群中确定与慢性病 (CKD) 相关的风险因素.
主要方法:
- 这是一项多中心的回顾性队列研究,涉及来自西班牙36家医院的789名原发性阿尔多斯特龙症患者.
- 患者接受单边上腺切除术 (41.8%) 或MRA (58.2%) 的治疗.
- 功能 (eGFR) 和白色素尿被评估在诊断时和在30.7个月的中位随访期间.
主要成果:
- 10.7%的患者在诊断时患有CKD,与更长时间的高血压,糖尿病,脂质失调,心血管事件,低血量和白尿有关.
- 上腺切除术和MRA治疗都导致估计的淋巴细胞过率 (eGFR) 的初始下降.
- 上腺切除术显示出更好的保护趋势,与MRA治疗相比,白蛋白尿的发展显著减少 (0%vs6.0%).
结论:
- 慢性瘤在原发性阿尔多斯特隆症中普遍存在,与特定的并发性疾病有关.
- 虽然这两种治疗最初都能降低EGFR,但上腺切除术似乎能提供优越的长期脏保护,特别是在预防白尿方面.
- 早期诊断和适当的治疗对于管理原发性阿尔多斯特症的结果至关重要.
相关概念视频
Antihypertensive Drugs: Direct Renin Inhibitors
528
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
528
Antihypertensive Drugs: Potassium-Sparing Diuretics
495
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
495
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
414
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
414
Antihypertensive Drugs: Angiotensin II Receptor Blockers
683
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
683
Hormonal Regulation
33.0K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
33.0K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
589
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
589

